RPRX
Royalty Pharma Plc
58.20$
-0.1%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +11.1% | -4.7% | -5.4% | +5.1% | +5.1% | -4.3% | +1.8% | +5.3% | +2.1% | +1.4% | +6.9% | – | |
| – | -72.4% | +662.7% | -99.0% | +3,693.4% | -27.9% | -22.5% | +60.4% | -99.4% | -6.3% | -2.1% | +22,804.9% | – | |
| – | +11.1% | -4.7% | -5.4% | +5.1% | +5.1% | -4.3% | +1.8% | +5.3% | +2.1% | +1.2% | -35.5% | – | |
| – | -99.0% | +0.0% | +0.0% | +0.0% | +0.0% | +10,000.0% | +495.0% | -83.2% | +1.0% | -21.6% | +144.6% | – | |
| – | +3.4% | -2.6% | -5.1% | +3.7% | +19.2% | +63.8% | +62.4% | -34.0% | +38.4% | -3.2% | +1.8% | – | |
| – | -104.4% | – | -58.3% | -163.7% | – | -85.3% | +982.8% | -50.6% | +28.3% | -101.3% | – | – | |
| – | +304.7% | -112.0% | – | +172.6% | -50.8% | +47.8% | -60.7% | +103.6% | -9.1% | +62.9% | -79.0% | – | |
| – | +2.7% | -6.4% | +10.8% | +35.7% | -1.1% | -0.8% | +5.2% | +15.9% | +18.4% | -0.5% | -0.1% | – | |
| – | +487.8% | -100.6% | – | +314.8% | -58.5% | +29.6% | -79.1% | +390.1% | -19.9% | +31.6% | -82.6% | – | |
| – | +346.3% | -104.1% | – | +184.0% | -52.0% | – | – | +158.0% | -9.0% | +21.8% | – | – | |
| – | +585.5% | -99.0% | +2,034.9% | +433.3% | -61.7% | +14.5% | -87.3% | +855.1% | -25.7% | +37.7% | -93.9% | – | |
| – | +355.0% | -94.8% | +509.1% | +258.6% | -54.2% | +24.6% | -68.1% | +229.6% | -14.1% | +24.8% | -68.7% | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.